Laboratory Profile of Hepatitis B and C in Users of a Reference Service

This study has been completed.
Sponsor:
Information provided by:
UPECLIN HC FM Botucatu Unesp
ClinicalTrials.gov Identifier:
NCT00512941
First received: August 6, 2007
Last updated: September 4, 2008
Last verified: September 2008

August 6, 2007
September 4, 2008
June 2007
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00512941 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Laboratory Profile of Hepatitis B and C in Users of a Reference Service
Laboratory Profile of Hepatitis B and C in Users of a Reference Service

Chronic hepatitis by the B virus (HBV) and/or by the C virus (HCV) is a major public-health problem since it presents a long phase of clinical latency which makes its early diagnosis difficult and results in the development of a large number of cases to complications such as cirrhosis, hepatic insufficiency and hepatocarcinoma. In Brazil, it is estimated that the number of HBV is two million, of which 72 thousand have been reported. As regards HCV, the ratio is one of three million estimated cases to 52 thousand reports. Learning about the serological profile of the users of a viral hepatitis reference service is fundamental for the planning of diagnostic and caregiving actions; therefore, it is the objective of this study.

Chronic hepatitis by virus B (HVB) and/or by virus C (HVC) is a major public-health problem since it presents a long phase of clinical latency which makes its early diagnosis difficult and results in the development of a large number of cases to complications such as cirrhosis, hepatic insufficiency and hepatocarcinoma. In Brazil, it is estimated that the number of HVB patients is two million, but only 72 thousand have been reported. As regards HVC, the ratio is three million estimated cases to 52 thousand reports. Learning about the serological profile of the users of a viral hepatitis reference service is essential for the planning of diagnostic and therapeutic actions; therefore, it is the objective of this study.

Five hundred and thirty-one HVB and HVC serological profiles of the patients referred to SAE/HD within a period of 18 months (January 2006 to June 2007) were studied by means of retrospective analysis. The patients were classified as: a) HBV: carrier, cure, isolated anti-HBc and vaccinated; b) HVC: reagent anti-HVC; c) HBV/HVC co-infection: AgHBs and reagent anti-HVC; and d) Susceptible: non-reagent serology.

As regards HBV, the following were found from the total number of patients: carriers, 12.6%; cure, 18.9%; isolated anti-HBc, 9.0% and vaccinated, 6.2%. The patients with reagent anti-HVC comprised 31.3% of the total number of individuals. HBV/HCV co-infection was 0.6%. Susceptible individuals comprised 20.5%.

It was concluded that approximately 45% of the referred patients carried chronic infection by B and/or C virus, a condition which requires additional investigation and, in many instances, specific treatment. Strategies for early diagnosis are essential in order to prevent the intrinsic complications of such condition.

Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample

Patients with laboratory tests positive for hepatitis B and/or C

  • Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
  • Hepatitis B, Chronic
Not Provided
  • 1
    HBV: Carrier
  • 2
    HBV: cure
  • 3
    HBV: isolate anti-HBc
  • 4
    HBV: vaccinated
  • 5
    HCV: anti-HCV positive test
  • 6
    HBV/HCV co-infection
  • 7
    Susceptible individuals
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
531
August 2007
Not Provided

Inclusion Criteria:

  • Patients with laboratory tests positive for hepatitis B and/or C

Exclusion Criteria:

  • No laboratory tests available
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Brazil
 
NCT00512941
upeclin/HC/FMB-Unesp-15
Yes
Sergio Muller, Faculdade de Medicina de Botucatu - Unesp
UPECLIN HC FM Botucatu Unesp
Not Provided
Principal Investigator: Alexandre N Barbosa, MD, MSc SAE e Hospital Dia de Aids
UPECLIN HC FM Botucatu Unesp
September 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP